EP3781132
Apixaban-samsetningar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
15.4.2019EP published:
20.3.2024EP application number:
19722333.2
EP translation filed:
13.5.2024Grant published:
15.6.2024EPO information:
European Patent Register
Max expiry date:
14.4.2039Expiry date:
14.4.2026Next due date:
30.4.2026
Title in English:
APIXABAN FORMULATIONSLanguage of the patent:
English
Timeline
Today
15.4.2019EP application
20.3.2024EP Publication
13.5.2024Translation submitted
15.6.2024Registration published
14.4.2026Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 & Province Line Road, Princeton, NJ 08543, US
Name:
Pfizer Inc.Address:
66 Hudson Boulevard East, New York, NY 10001-2192, US
Inventor
Name:
BADAWY, Sherif, Ibrahim, FaragAddress:
Princeton, NJ 08543-4000, US
Name:
STEVENS, Timothy, D.Address:
Princeton, NJ 08543-4000, US
Name:
KUNTZ, DanielAddress:
Princeton, NJ 08543-4000, US
Name:
WAYBRANT, BrettAddress:
Princeton, NJ 08543-4000, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862658175 PDate:
16.4.2018Country:
US
Classification
Categories:
A61K 9/16, A61K 31/4545, A61P 7/02
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 22.4.2024
Expires: 14.4.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 14.3.2025
Expires: 14.4.2026
Payer: Árnason Faktor ehf.